39.94
3.42%
+1.32
Ideaya Biosciences Inc stock is currently priced at $39.94, with a 24-hour trading volume of 614.98K.
It has seen a +3.42% increased in the last 24 hours and a -6.05% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $38.79 pivot point. If it approaches the $40.91 resistance level, significant changes may occur.
Previous Close:
$38.62
Open:
$38.9
24h Volume:
614.98K
Market Cap:
$2.99B
Revenue:
$23.38M
Net Income/Loss:
$-112.96M
P/E Ratio:
-27.54
EPS:
-1.45
Net Cash Flow:
$-117.59M
1W Performance:
+7.57%
1M Performance:
-6.05%
6M Performance:
+47.60%
1Y Performance:
+116.83%
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
7000 Shoreline Court, Suite 350, South San Francisco, CA
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-23 | Initiated | SVB Securities | Outperform |
May-24-23 | Initiated | Goldman | Buy |
Apr-24-23 | Upgrade | Stifel | Hold → Buy |
Mar-23-23 | Initiated | Berenberg | Buy |
Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
Dec-28-22 | Initiated | CapitalOne | Overweight |
Oct-27-22 | Initiated | Citigroup | Buy |
Aug-15-22 | Downgrade | Stifel | Buy → Hold |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mar-10-22 | Upgrade | Stifel | Hold → Buy |
Sep-23-21 | Initiated | Stifel | Hold |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Mar-11-21 | Initiated | Guggenheim | Buy |
Oct-07-20 | Initiated | Wedbush | Outperform |
Sep-01-20 | Initiated | Northland Capital | Outperform |
Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
Apr-06-20 | Initiated | H.C. Wainwright | Buy |
Mar-13-20 | Initiated | ROTH Capital | Buy |
Oct-17-19 | Initiated | Oppenheimer | Outperform |
Sep-10-19 | Initiated | Robert W. Baird | Outperform |
Jun-17-19 | Initiated | Citigroup | Buy |
Jun-17-19 | Initiated | JP Morgan | Neutral |
Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts
Benzinga
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
Zacks Investment Research
Critical Insights From IDEAYA Biosciences Analyst Ratings: What You Need To Know
Benzinga
8 Analysts Have This to Say About IDEAYA Biosciences
Benzinga
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Ideaya Biosciences Inc (IDYA) Revenue 2024
IDYA reported a revenue (TTM) of $23.38 million for the quarter ending December 31, 2023, a -54.09% decline year-over-year.
Ideaya Biosciences Inc (IDYA) Net Income 2024
IDYA net income (TTM) was -$112.96 million for the quarter ending December 31, 2023, a -92.59% decrease year-over-year.
Ideaya Biosciences Inc (IDYA) Cash Flow 2024
IDYA recorded a free cash flow (TTM) of -$117.59 million for the quarter ending December 31, 2023, a -29.77% decrease year-over-year.
Ideaya Biosciences Inc (IDYA) Earnings per Share 2024
IDYA earnings per share (TTM) was -$1.97 for the quarter ending December 31, 2023, a -41.73% decline year-over-year.
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):